High-dose therapy. Experience of the non-Hodgkin’s lymphoma Co-operative Study Group (NHLCSG)

Published: June 8, 2009
Abstract Views: 139
PDF: 118
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In aggressive, advanced stage non-Hodgkin’s lymphoma (NHL), 2nd and 3rd generation regimens gave results similar to those observed with CHOP therapy with a CR of approximately 50%, a 3-year survival probability of approximately 50% and a PFS of 35-40%. In order to improve outcome of these patients we started the 1st our study on the use of high-dose therapy as front-line therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Santini, G. (2009). High-dose therapy. Experience of the non-Hodgkin’s lymphoma Co-operative Study Group (NHLCSG). Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.422